Navigation Links
Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

mon shareholders was $4.7 million, or $0.23 per diluted share, up 193.1% from $1.6 million, or $0.08 per diluted share, for the same period in 2010.

Balance Sheet:  As of September 30, 2011, cash and cash equivalents grew to $71.1 million, compared to $69.8 million at June 30, 2011. Total assets grew from $94.6 million on June 30, 2011 to $96.1 million as of September 30, 2011. Cumberland's total debt as of September 30, 2011, declined to $4.6 million from $5.8 million at June 30, 2011.

"Our financial performance in the third quarter of 2011 was strong, with our net income increasing 83% over the prior year period," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals.  "We achieved many milestones this quarter – including reaching an agreement to acquire the trademark and approved FDA registration for Kristalose, the appointment of Rick S. Greene as Chief Financial Officer, and the signing of new international product agreements – while maintaining strong sales of Acetadote and progressing our clinical trial programs. Our goal at Cumberland continues to be maintaining a financial discipline while delivering solid financial results and laying the ground work for future growth opportunities."

Based on its third quarter performance, Cumberland is reaffirming its full year 2011 revenue guidance of $51 - $55 million. This guidance represents the Company's best estimate of future results, which may be affected by factors described below in "Forward-Looking Statements."

Company Highlights Acetadote®

New Formulation

In January 2011, the U.S. Food and Drug Administration (FDA) approved Cumberland's supplemental new drug application (sNDA) for a new formulation of Acetadote, which was the result of a phase IV commitment the Company made to the FDA upon receipt of initial marketing approval of the product. The new formulation does not contain Ethylene diam
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
2. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
3. Cumberland Pharmaceuticals Appoints Lee Product Director
4. Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
5. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
6. Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
7. Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock
8. Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  Oxis Biotech, Inc. (OXIS), ... OXIS, OXI.PA, announced today that Cassian Yee , ... Cancer Medicine at the University of Texas MD Anderson ... is also Professor, Department of Immunology, Division of Cancer ... Cancer Immunology Research at the University of Texas MD ...
(Date:5/6/2015)... Portland, OR (PRWEB) May 06, 2015 ... executive search and growth strategy for the specialty pharmacy ... Sponser of the 2015 Armada Specialty Pharmacy Summit. The ... Wynn Hotel in Las Vegas and is the largest ... people will be in attendance, from pharmacy providers, pharma/biotech ...
(Date:5/5/2015)... May 5, 2015  23andMe, Inc., the leading personal ... Lupus Research Study in collaboration with Pfizer Inc. ... lupus erythematosus, more commonly known as lupus, into the ... The effort is also in collaboration with the Lupus ... in May. Approximately 1.5 million people in ...
(Date:5/5/2015)... , May 5, 2015  Tikcro Technologies ... was approved to continue trading on OTCQB  Marketplace, ... OTCQB Marketplace allows for a continuous public ... Investors can have real-time quotes and market information ... The OTCQB Marketplace includes U.S. and international ...
Breaking Biology Technology:Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2
... 23 Pharmaceutical and biotech partners tasked with cutting costs and improving ... What are the implications of the current economic ... can I harness the knowledge of all employees to improve processes cross-functionally? ... methodologies do I use to show the revenue of quality instead of ...
... WYE ) announced today that it will ... Stock, par value $2.50 per share (the "Convertible Preferred ... As of April 22, 2009, there were 8,896 ... each share of Convertible Preferred Stock is $60.08, which ...
... Provide Proprietary Protein and Small Molecule Products for ... Stem (iPS) CellsLA JOLLA, Calif. and BOSTON, April ... and Stemgent, Inc. ... one-of-a-kind program to provide pharmaceutical and biotechnology companies ...
Cached Biology Technology:Cost-Cutting Plus Value-Add Defines Quality's Role in a Recession 2Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 2Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 3Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 4Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 5Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 2Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 3Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 4
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/26/2015)... March 26, 2015 The Granite ... recreation and athletic club, today announced it has implemented ... freedom of movement for members and staff, while restricting ... comprehensive process, we selected FST,s IMID Access system because ... for our members and staff, in addition to unparalleled ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... in the open-access journal PLoS Biology, streamlines the computation ... genome that influence a particular physical trait, or phenotype. ... Joshua M. Akey, and Leonid Kruglyak, researchers have a ... the genomic elements that produce specific traits. , In ...
... gene therapy can promote the growth of new "insulation" around ... new study shows. The treatment, which mimics the activity of ... and electrical conduction from the brain to the leg muscles. ... spinal cord injury in humans. The study was funded in ...
... results of a study conducted at Johns Hopkins show that ... attacks, or myocardial infarction, in pigs. In just two months, ... into the animal's damaged heart restored heart function and repaired ... The Hopkins findings, first presented last fall at the 2004 ...
Cached Biology News:Improved statistical tools reveal many linked loci 2Combination therapy leads to partial recovery from spinal cord injury in rats 2Combination therapy leads to partial recovery from spinal cord injury in rats 3Stem cell therapy successfully treats heart attack in animals 2
Mol wt: average mol wt12,360.96 Da by calculation...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... Adaptor encodes a T7 promoter, lac ... translation initation codon and an N-terminal GST•Tag ... reported to enhance the production and in ... partners. The GST•Tag is a multi-purpose tag ...
A cost-effective serum for general cell growth requirements. All serum is collected from calves aged 10 days old or less....
Biology Products: